Lupin 获得 FDA 批准用于 Phytonadione 注射乳剂
Lupin Limited 已获得美国食品药品监督管理局（FDA）对其Phytonadione Injectable Emulsion的ANDA批准，表明其与参照药物具有生物等效性，并获批用于治疗低凝血素血症和维生素K缺乏症。
为什么重要. Lupin的Phytonadione Injectable Emulsion获批扩大了其产品组合，并加强了其在美国制药市场中的地位。
深度阅读深度解读
01
影响到谁
- 1Lupin Limited
- 位于 →事实
02
证据
- PPR Newswire news releases公司披露2026-10-09 03:16
The U.S. FDA has approved Lupin's Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-dose Prefilled Syringe
- PPR Newswire news releases公司披露2026-10-09 03:16
Phytonadione Injectable Emulsion had estimated annual sales of USD 52.3 million in the U.S. (IQVIA MAT Aug 2026).
- GGDELT Global Knowledge Graph媒体2026-10-09 03:45
- GGDELT Global Knowledge Graph媒体2026-10-09 04:15
- GGDELT Global Knowledge Graph媒体2026-10-09 04:15
- GGDELT Global Knowledge Graph媒体2026-10-09 04:15
- GGDELT Global Knowledge Graph媒体2026-10-09 03:45
- GGDELT Global Knowledge Graph媒体2026-10-09 04:15
- GGDELT Global Knowledge Graph媒体2026-10-09 04:15
- GGDELT Global Knowledge Graph媒体2026-10-09 04:15
- GGDELT Global Knowledge Graph媒体2026-10-09 04:15
- GGDELT Global Knowledge Graph媒体2026-10-09 03:45